Market Overview

UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on Aegerion Pharmaceuticals

Related AEGR
Meet The Biopharma Stock That Lost 34% Last Week
Midday Losers From October 31: Aegerion Pharmaceuticals, Bottomline Technologies, Digital Globe

In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised its price target from $27.00 to $36.00.

Canaccord Genuity noted, “AEGR announced additional Juxtapid launch color, with the key takeaways being the $235K/$295K U.S. annual pricing (vs. our $250K estimate) for initiation/maintenance, respectively, and that >1,500 patients have been identified worldwide to date through the registry. As a result, we believe AEGR's goal of 250-300 patients on drug by YE13 and $15M - $25M FY13 revenue guidance (we model for $22M) could prove conservative. We have adjusted our model to account for the higher pricing and a slower 2013 ramp but increased revenue in 2014+.”

Aegerion Pharmaceuticals closed on Tuesday at $25.76.

Latest Ratings for AEGR

DateFirmActionFromTo
Oct 2014NeedhamDowngradesBuyHold
Oct 2014JefferiesDowngradesBuyHold
Oct 2014JP MorganDowngradesOverweightNeutral

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (AEGR)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional